JAK2 and B-cell chronic lymphocytic leukemia: In addition, inhibition of JAK2 or BTK, downstream effectors of CXCL12, inhibits integrin activation and suppresses tumor cell adhesion, survival, and spread in B-cell chronic lymphocytic leukemia (B-CLL) [204].